Dechra Pharmaceuticals, a global specialist veterinary pharmaceuticals business, agreed to acquire Invetx, a specialist in protein-based therapeutics for animal health, for $520m. “Invetx’s ability to develop veterinary biotherapeutics with an extended duration of effect and longer inter-dosing intervals represents a significant innovation in animal health. The Invetx products in development have significant potential and will deepen our expertise in core therapeutic areas such as atopic dermatitis and osteoarthritis, allowing for synergistic product development, sales and marketing, and education efforts in the future,” Jesper Nordengaard, Dechra CEO.